Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,537 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Like Clear all
Terminated Phase 3 Interventional Results available

Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology

NCT00596830
View directory record Official record
Conditions
Carcinoma, Squamous Cell, Carcinoma, Adenosquamous, Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung
Interventions
CP-751,871 (Figitumumab), Carboplatin, Paclitaxel
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
169
States / cities
Florence, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 133 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Oct 21, 2026, 5:26 PM EDT
Recruiting Not applicable Interventional

Evaluation of Combination Therapy for Upper Extremity Lymphedema

NCT05825157
View directory record Official record
Conditions
Lymphedema Arm
Interventions
BioBridge
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 21, 2026, 5:26 PM EDT
Active, not recruiting Not applicable Interventional

Blood Flow Monitoring to Prevent Post-Polypectomy Induced Ulcer Bleeding

NCT02875353
View directory record Official record
Conditions
Delayed Post-Polypectomy Induced Ulcer Hemorrhage
Interventions
Doppler Endoscopic Probe
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
35 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
3
States / cities
Downey, California • Los Angeles, California • West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 21, 2026, 5:26 PM EDT
Completed No phase listed Observational

Breast Cancer Registry for Participants With Breast Cancer or Characteristics of Hereditary Breast Cancer

NCT00666731
View directory record Official record
Conditions
Breast Cancer, Precancerous Condition
Interventions
medical chart review, questionnaire administration, study of socioeconomic and demographic variables, Excess human biological tissue, quality-of-life assessment
Other · Procedure
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years
Enrollment
4,945 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
65
States / cities
Colorado Springs, Colorado • Denver, Colorado • Lakewood, Colorado + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 21, 2026, 5:26 PM EDT
Enrolling by invitation Not applicable Interventional

To Drill or Not to Drill: Do Memory Drills Help Train the Ability to "Remember to Remember" in Veterans

NCT06656637
View directory record Official record
Conditions
Memory Deficit
Interventions
Memory Drilling, Compensatory Strategies, Cognitive Processing Therapy
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 21, 2026, 5:26 PM EDT
Completed No phase listed Observational

Williams Syndrome (WS) and Supravalvar Aortic Stenosis (SVAS) DNA and Tissue Bank

NCT02706639
View directory record Official record
Conditions
Williams Syndrome, Supravalvular Aortic Stenosis, Cardiovascular Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
1 Day to 85 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
3
States / cities
Bethesda, Maryland • St Louis, Missouri • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 21, 2026, 5:26 PM EDT
Completed Phase 4 Interventional Results available

Liraglutide Effects on Epicardial Fat Inflammatory Genes

NCT03260881
View directory record Official record
Conditions
Type2 Diabetes, Coronary Artery Disease
Interventions
Liraglutide Pen Injector [Victoza], matching liraglutide-placebo pre-filled pens
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Oct 21, 2026, 5:26 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus)

NCT06792500
View directory record Official record
Conditions
MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus)
Interventions
Glycerol Tributyrate
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 21, 2026, 5:26 PM EDT
Completed Phase 2 Interventional Results available

Growth Hormone Treatment in Children With Phelan McDermid Syndrome

NCT04003207
View directory record Official record
Conditions
Phelan McDermid Syndrome
Interventions
Recombinant human Growth hormone
Drug
Lead sponsor
Swathi Sethuram
Other
Eligibility
2 Years to 12 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Oct 21, 2026, 5:26 PM EDT
Completed Phase 4 Interventional Results available

Study of Metoclopramide in Small Bowel Capsule Endoscopy

NCT01630109
View directory record Official record
Conditions
Pill Capsule Endoscopy Completion Rates
Interventions
Metoclopramide, Placebo
Drug
Lead sponsor
Ascension Health
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Grand Blanc, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Oct 21, 2026, 5:26 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab

NCT00845039
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer
Interventions
Cetuximab, Irinotecan, IMC-A12 (cixutumumab)
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Vallejo, California • Greenville, North Carolina • Scranton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 21, 2026, 5:26 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Acute Respiratory Infection Consortium

NCT01021098
View directory record Official record
Conditions
Influenza
Interventions
Not listed
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
17 Years to 55 Years
Enrollment
2,018 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2023
U.S. locations
5
States / cities
San Diego, California • Bethesda, Maryland • San Antonio, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2023 · Synced Oct 21, 2026, 5:26 PM EDT
Recruiting Phase 2 Interventional

A Study of Tarlatamab for People With Prostate Cancer

NCT07111507
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
Tarlatamab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • Basking Ridge, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 21, 2026, 5:26 PM EDT
Completed Not applicable Interventional

ABC Brain Games Self-Regulation Intervention

NCT03060863
View directory record Official record
Conditions
Obesity, Self-Regulation
Interventions
2. Executive Functioning, 3. Food Bias, 4. Emotion Regulation, 5. Future orientation
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
9 Years to 12 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 21, 2026, 5:26 PM EDT
Completed Not applicable Interventional

Improving Neurodevelopment in Adolescents With Congenital Heart Disease

NCT02759263
View directory record Official record
Conditions
Congenital Heart Disease, Neurodevelopment, Executive Function, Working Memory Training, Infant Open-heart Surgery
Interventions
Cogmed Working Memory Training
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
13 Years to 16 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 21, 2026, 5:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Theta Burst Stimulation on the Brain, Behavior, and Clinical Symptoms in Adults With Bipolar Disorder

NCT04696471
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Continuous Theta Burst Stimulation (cTBS), Sham Continuous Theta Burst Stimulation (Sham cTBS)
Device
Lead sponsor
Mary Phillips, MD MD (Cantab)
Other
Eligibility
18 Years to 35 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 21, 2026, 5:26 PM EDT
Enrolling by invitation No phase listed Observational

Achilles Non-SNIS REGENETEN

NCT07869121
View directory record Official record
Conditions
Complete Mid-portion Achilles Rupture
Interventions
REGENETEN
Device
Lead sponsor
OrthoCarolina Research Institute, Inc.
Other
Eligibility
21 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 21, 2026, 5:26 PM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

NCT02883049
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Central Nervous System Leukemia, Testicular Leukemia
Interventions
Clofarabine, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Hydrocortisone Sodium Succinate, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
Drug · Other · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 31 Years
Enrollment
5,949 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
209
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 21, 2026, 5:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

FirstStep2Health Intervention

NCT04164277
View directory record Official record
Conditions
Pediatric Obesity, Risk Reduction Behavior, Early Intervention, Intergenerational Relations
Interventions
Caregiver Component., Caregiver-Preschooler Learning., Center-based Preschooler Component.
Behavioral
Lead sponsor
Michigan State University
Other
Eligibility
3 Years to 5 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 2, 2024 · Synced Oct 21, 2026, 5:26 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Dipeptidyl Peptidase-4 Inhibition on Glucagon-like Peptide-1 (GLP-1)

NCT00947011
View directory record Official record
Conditions
Glucose Homeostasis
Interventions
Placebo, Januvia
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Oct 21, 2026, 5:26 PM EDT
Completed Phase 3 Interventional Results available

Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency

NCT00125164
View directory record Official record
Conditions
Growth Disorders, Insulin-Like Growth Factor-1 Deficiency
Interventions
rhIGF-1 (mecasermin, Tercica, Inc.)
Drug
Lead sponsor
Ipsen
Industry
Eligibility
3 Years to 12 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Oct 21, 2026, 5:26 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1

NCT00577577
View directory record Official record
Conditions
Myotonic Dystrophy Type 1
Interventions
rhIGF-I/rhIGFBP-3, placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
21 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
12
States / cities
Orange, California • Sacramento, California • Kansas City, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2022 · Synced Oct 21, 2026, 5:26 PM EDT
Completed Phase 2 Interventional Results available

Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)

NCT01327612
View directory record Official record
Conditions
Advanced Solid Tumors, Carcinoid, Colorectal Cancer, Locally Advanced, Lymphoma, Metastatic Cancer, Non-Small Cell Lung Cancer, Sarcoma, Solid Tumors
Interventions
Modified FOLFOX6, Conatumumab, Ganitumab, Bevacizumab
Drug · Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
10
States / cities
Duarte, California • La Jolla, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 21, 2026, 5:26 PM EDT
Completed Phase 3 Interventional Results available

The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

NCT01617434
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
31
States / cities
Phoenix, Arizona • Anaheim, California • Fresno, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 21, 2026, 5:26 PM EDT